<DOC>
	<DOCNO>NCT02907749</DOCNO>
	<brief_summary>The aim study investigate effect spironolactone liver fibrosis progression portal hypertension patient compensate cirrhosis . The patient nonrandomized accord medical condition determine physician , 3 arm ( spironolactone start 40mg daily increase every week maximum dose 100mg daily , carvedilol start 6.25mg daily increase 12.5mg daily next week tolerate , spironolactone combination carvedilol : spironolactone add carvedilol reach tolerate dose ) . Portal pressure gradient virtual hepatic venous pressure gradient base enhanced CT , liver elasticity Fibroscan Medical Device document baseline level every six month treatment . Changes serum fibrosis marker liver function monitor every 3 month treatment .</brief_summary>
	<brief_title>Spironolactone Fibrosis Progrssion-Portal Hypertension ( FP-PH ) Cirrhosis</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Hypertension , Portal</mesh_term>
	<mesh_term>Carvedilol</mesh_term>
	<mesh_term>Spironolactone</mesh_term>
	<criteria>Proven compensate cirrhosis base histology unequivocal clinical , sonographic laboratory finding Proven portal hypertension calculate virtual HVPG &gt; 12mmHg base enhance CT ChildPugh score &lt; 9 Suspension alcohol intake least 6 week enrollment Treatment angiotensin II receptor antagonist angiotensin convert enzyme inhibitor last 2 month Renal insufficiency Hepatic encephalopathy stage 2 Contraindications betablockers spironolactone . Other organ fibrosis situation Malignant diseases Portal vein thrombosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>